Cetuximab 5mg/mL Solution for Infusion

Prescribed Criteria: Consultant Oncologist

Inpatient use:

1. Treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer
   - In combination with irinotecan-based chemotherapy
   - First-line in combination with FOLFOX
   - As a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.

2. Squamous cell cancer of the head and neck
   - In combination with radiation therapy for locally advanced disease,
   - In combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

Duration of Approval:
1 year